What Plexium does

Plexium, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California (Delaware-incorporated), founded in 2018, that develops targeted protein degradation (TPD) therapeutics for oncology. The company's pipeline focuses on small-molecule monovalent direct degraders and molecular glue degraders that hijack the cellular ubiquitin-proteasome system to eliminate disease-driving proteins, including targets historically considered undruggable. Its lead clinical programs include PLX-61639, an oral SMARCA2-selective direct degrader for SMARCA4-mutated solid tumors, and PLX-4545, an oral IKZF2 molecular glue degrader for immune-checkpoint combination therapy; a third asset, PLX-66140, is an oral CDK2 molecular glue degrader in earlier development for ER+/Her2- breast cancer and CCNE1-amplified tumors.

The company's discovery engine is the DELTA Discovery™ platform, which integrates proprietary degrader chemistry design, ultra-high throughput cell-based screening using miniaturized Picowell devices, AI-guided structure-based drug design, and degrader-centric CRISPR knockout screens that have yielded multiple internally identified novel E3 ligases and a 1+ million-member on-bead Cereblon binder library. Plexium's revenue model is pre-commercial: it monetizes the platform through upfront fees, R&D funding, milestones, and potential royalties under multi-year pharmaceutical collaborations — most notably a multi-year research collaboration and license agreement with Amgen signed in February 2022 alongside a $102M financing round — supplemented by equity capital from institutional venture investors. Patients access the company's investigational medicines exclusively via participation in registered clinical trials (e.g., NCT07284186, ANZCTR-12623001265662); no products are commercially approved or priced.

Name

Plexium

Legal name

Plexium, Inc.

Website

https://plexium.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Plexium is a privately held, clinical-stage biopharmaceutical company developing orally bioavailable monovalent and molecular glue targeted protein degraders for oncology, with lead programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) in Phase 1 trials, powered by its proprietary DELTA Discovery™ platform.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Targeted protein degradation
• Protein degrader therapeutics
• Monovalent direct degraders
• Molecular glue degraders
• Oncology drug discovery

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Research Collaboration and Licensing Revenue: Multi-year research collaboration and license deals with pharmaceutical partners, including milestone payments, upfront fees, and potential royalties on commercialized products. Plexium announced a collaboration and license deal with Amgen to develop targeted protein degradation therapeutics.
2. Equity Financing: Company has raised significant equity capital through funding rounds ($102M in 2022) and SEC Form D filings for exempt securities offerings ($60M+ in 2025) to fund R&D and clinical development operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Plexium is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics, including monovalent direct degraders and molecular glue degraders. Its pipeline includes clinical-stage programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) and earlier-stage PLX-66140 (CDK2), all powered by its proprietary DELTA Discovery platform for oncology indications.

Product overview

Plexium is a premier next-generation targeted protein degradation (TPD) company that develops monovalent targeted protein degrader therapeutics. The company's offering consists of the DELTA Discovery™ Platform, which powers drug discovery through proprietary ultra-high throughput cell-based screening, combined with two degrader modalities: Monovalent Direct Degraders and Molecular Glue Degraders. The pipeline includes clinical-stage programs PLX-61639 (SMARCA2 direct degrader) and PLX-4545 (IKZF2 molecular glue degrader), along with PLX-66140 (CDK2 molecular glue) in earlier development, all focused on addressing high unmet medical needs in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• DELTA Discovery Platform A proprietary drug discovery platform integrating degrader chemistry design principles with ultra-high throughput cell-based screening to identify drug-like, cell-permeable monovalent degrader drug candidates for internal pipeline and partnership programs.
• PLX-61639 (SMARCA2 Degrader) An oral SMARCA2-selective direct degrader in Phase 1 clinical development for the treatment of patients with SMARCA4-mutated locally advanced or metastatic solid tumors.
• PLX-4545 (IKZF2 Molecular Glue Degrader) An oral IKZF2-selective molecular glue degrader in Phase 1 clinical development as monotherapy and in combination to improve clinical responses to immune checkpoint inhibitors across multiple solid tumor types.
• PLX-66140 (CDK2 Molecular Glue Degrader) A potent, highly selective and orally bioavailable CDK2 molecular glue degrader in preclinical/early development for ER+, Her2- breast cancer and CCNE1-amplified tumor types.

Quantifiable outcome

• SMARCA4 loss of function mutations occur in 5-7% of all human cancers
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• AmgencoreStrategic or Co-development Partner · 23 February 2022Multi-year research collaboration and license deal with Amgen to develop targeted protein degradation therapeutics. Plexium received $102 million in funding alongside this collaboration, combining Amgen's pharmaceutical capabilities with Plexium's targeted protein degradation expertise.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arvinas: Clinical-stage leader in targeted protein degradation using PROTAC technology, with multiple oncology programs in Phase 1-3 trials. Directly comparable to Plexium as a TPD platform company developing small-molecule degraders for previously 'undruggable' oncology targets.
• Kymera Therapeutics: Clinical-stage biopharmaceutical company developing targeted protein degraders with a focus on immunology and oncology. Closely comparable to Plexium on TPD modality, platform-driven pipeline expansion, and clinical-stage execution.
• Nurix Therapeutics: Clinical-stage company developing targeted protein modulators using both degraders and stabilizers, with significant focus on molecular glue degraders using Cereblon-based chemistry — directly analogous to Plexium's glue degrader approach.
• C4 Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule degraders using both monomeric (degronimids) and dimeric (PROTAC) approaches for oncology targets. Closely comparable to Plexium on TPD modality and clinical-stage pipeline.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders, with emphasis on leveraging cereblon and other E3 ligases for oncology and immunology indications. Directly comparable on molecular glue degrader modality and undruggable target focus.
• Foghorn Therapeutics: Clinical-stage oncology company focused on chromatin biology and protein degradation. Comparable to Plexium in using platform-driven discovery for previously undruggable oncology targets, though Foghorn emphasizes chromatin regulatory proteins.

Emerging players

• Amphista Therapeutics: Emerging European-based targeted protein degradation company developing next-generation TPDs with novel mechanisms beyond traditional PROTACs. Comparable as an emerging TPD platform competitor with novel E3 ligase ambitions.
• BioTheryX: Clinical-stage company developing targeted protein degraders and modulators using small molecules, including PHM (pharmacological hybrid modulators). Emerging competitor in the TPD space with overlap to Plexium's monovalent degrader approach.
• Salarius Pharmaceuticals: Clinical-stage oncology company developing targeted protein degraders, including SP-3164 (formerly Avadomide) and preclinical programs. Smaller-scale comparable to Plexium as a clinical TPD developer focused on hematologic and solid tumor indications.

Broad incumbents

• Amgen: Large-cap biopharmaceutical company with broad oncology and protein degradation capabilities, and Plexium's strategic collaboration and license partner. Included as a broad incumbent that operates in the same oncology space and validates the platform via partnership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/plexium
• Xx.com/plexiumtx
• Facebookfacebook.com/Plexium-102140614535000

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plexium